What it’s about
The Cut Stack combines three mechanistically independent compounds from metabolic research. Instead of using multiple compounds of the same class in parallel, the stack addresses three distinct axes: central appetite regulation, amylin-mediated satiety signals and direct lipolysis in adipocytes.
The community combines these three pathways because they do not overlap but complement each other. In preclinical studies, the combination of GLP-1 agonist plus amylin analog plus peripheral lipolytic compound is investigated as an established three-axis setup for obesity research.
The Compounds
Tirzepatide is a dual GLP-1 and GIP receptor agonist. In preclinical and clinical studies, the compound has been associated with substantial effects on glucose homeostasis, appetite regulation and adipocyte volume. Addresses the central appetite axis via brain-gut signaling.
Cagrilintide is an amylin analog and thus mechanistically independent of the GLP-1 family. In research models, the compound is associated with effects on satiety signals via the calcitonin receptor family pathway. Investigated in research literature explicitly as a complement to GLP-1 agonists.
AOD-9604 is a synthetic fragment of the C-terminus of HGH. In research models, the compound is associated with lipolytic activity in adipocytes, without the growth-promoting effects of the full HGH molecule. Addresses the peripheral adipocyte axis directly.
Research Context
The three-axis logic is mechanistically clean: Tirzepatide reduces hunger signals and improves glucose utilization, Cagrilintide extends the satiety axis via an independent receptor, AOD-9604 acts directly on adipose tissue without receptor overlap with the other two. In preclinical studies, the GLP-1 and amylin axes are explicitly characterized as complementary; peripheral lipolytic compounds extend coverage with a component independent of the central nervous system.
This information is for research and educational purposes only. No medical recommendations.